Compare LSAK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSAK | OBIO |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.8M | 238.3M |
| IPO Year | 2005 | 2020 |
| Metric | LSAK | OBIO |
|---|---|---|
| Price | $4.91 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 136.5K | ★ 247.1K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $659,701,000.00 | $33,482,000.00 |
| Revenue This Year | $14.35 | N/A |
| Revenue Next Year | $8.60 | $12.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.92 | ★ 1169.22 |
| 52 Week Low | $3.62 | $2.20 |
| 52 Week High | $5.54 | $5.42 |
| Indicator | LSAK | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.22 | 49.63 |
| Support Level | $4.76 | $3.95 |
| Resistance Level | $4.94 | $4.19 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 28.21 | 64.30 |
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.